180 related articles for article (PubMed ID: 37528032)
1. [Multidisciplinary treatment in the long-term management of Fabry disease].
;
Zhonghua Nei Ke Za Zhi; 2023 Aug; 62(8):949-955. PubMed ID: 37528032
[TBL] [Abstract][Full Text] [Related]
2. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
[TBL] [Abstract][Full Text] [Related]
3. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
[TBL] [Abstract][Full Text] [Related]
5. Stroke and Chronic Kidney Disease in Fabry Disease.
Tapia D; Kimonis V
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
[TBL] [Abstract][Full Text] [Related]
6. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
7. De novo mutation in a male patient with Fabry disease: a case report.
Iemolo F; Pizzo F; Albeggiani G; Zizzo C; Colomba P; Scalia S; Bartolotta C; Duro G
BMC Res Notes; 2014 Jan; 7():11. PubMed ID: 24398019
[TBL] [Abstract][Full Text] [Related]
8. Multidisciplinary approach to screening and management of children with Fabry disease: practice at a Tertiary Children's Hospital in China.
Shen Q; Liu J; Chen J; Zhou S; Wang Y; Yu L; Sun L; Wang L; Wu B; Liu F; Cao Y; Huang Y; Wang J; Yang C; Zhu D; Ma Y; Xu Z; Lu W; Fu L; Zhou W; Xu H
Orphanet J Rare Dis; 2021 Dec; 16(1):509. PubMed ID: 34906154
[TBL] [Abstract][Full Text] [Related]
9. Case report: is low α-Gal enzyme activity sufficient to establish the diagnosis of Fabry disease?
Biagini G; Almeida ACSF; Almeida TVR; Silva CAB; Castro BF; Reche TC; Dabinski AC; Barreto FC
J Bras Nefrol; 2017; 39(3):333-336. PubMed ID: 29044343
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
11. [A case of Anderson-Fabry disease: a multidisciplinary approach for diagnosis and follow up].
Zito A; De Pascalis A; Armeni A; Ria P; Barbarini L; Caggiula M; My F; Barbarini S; Trianni G; Napoli M
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234233
[TBL] [Abstract][Full Text] [Related]
12. The management and treatment of children with Fabry disease: A United States-based perspective.
Hopkin RJ; Jefferies JL; Laney DA; Lawson VH; Mauer M; Taylor MR; Wilcox WR;
Mol Genet Metab; 2016 Feb; 117(2):104-13. PubMed ID: 26546059
[TBL] [Abstract][Full Text] [Related]
13. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: diagnostic methods in nephrology practice.
Vujkovac B
Clin Nephrol; 2017 Supplement 1; 88(13):44-47. PubMed ID: 28601129
[TBL] [Abstract][Full Text] [Related]
16. [A boy with Fabry disease with the onset at the age of four].
Liu YP; Huang Y; Wang Q; Wu TF; Ma YY; Li XY; Song JQ; Yang YL
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):307-11. PubMed ID: 23591357
[TBL] [Abstract][Full Text] [Related]
17. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
18. [Management of Fabry disease].
Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
[TBL] [Abstract][Full Text] [Related]
19. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
20. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]